The Subject Expert Committee (SEC) under India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has accepted the Phase IV clinical trial report for Lenvatinib Capsules (4 mg and 10 mg) submitted by Eisai Pharmaceuticals India Private Limited.

The acceptance follows a comprehensive review of post-marketing safety data, including Serious Adverse Events (SAEs), presented by the company during a recent SEC meeting.

Regulatory Review and Compliance

The matter was reviewed in line with the committee’s earlier recommendation dated 17 June 2025, which required Eisai to submit additional safety information from the ongoing Phase IV clinical trial. In response, the company placed detailed SAE reports and its internal safety assessments before the committee.

After detailed deliberations, the SEC concluded that the submitted data was satisfactory and recommended acceptance of the Phase IV clinical trial study report for both strengths of Lenvatinib capsules.

Therapeutic Use and Mechanism of Action

Lenvatinib is a receptor tyrosine kinase inhibitor used in the treatment of multiple oncology indications, including metastatic thyroid cancer, advanced renal cell carcinoma (in combination with everolimus), and unresectable hepatocellular carcinoma.

The molecule acts by inhibiting key signalling pathways involved in tumour angiogenesis and cancer progression. It targets VEGF receptors (VEGFR1, VEGFR2, VEGFR3) and also suppresses other receptor tyrosine kinases such as FGFR 1–4, PDGFRα, KIT, and RET, which are associated with tumour growth and vascular development.

Also read: Early-Stage Nipah Virus Vaccine Trials Signal Progress in Pandemic Preparedness

Significance for Oncology Pharmacovigilance

The SEC’s acceptance of the Phase IV data reinforces the post-marketing safety profile of Lenvatinib in Indian patients and highlights the regulator’s continued emphasis on real-world safety monitoring for oncology therapies.

For pharmaceutical companies and healthcare stakeholders, the decision underscores the importance of robust pharmacovigilance systems and regulatory compliance in ensuring long-term patient safety while sustaining market access for critical cancer treatments.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!